ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, published by DE GRUYTER POLAND SP Z O O, stands as a pivotal journal in the field of immunology, contributing significantly to the advancement of knowledge and therapy in this crucial area of medicine since its inception in 1954. With an ISSN of 0004-069X and an E-ISSN of 1661-4917, the journal operates out of Switzerland, catering to an international audience of researchers, practitioners, and students. As reflected in its Scopus rankings, the journal is positioned within the third quartile in both Immunology and Allergy (Q3) and holds a commendable second quartile in Medicine (miscellaneous) (Q2), indicating its respectable influence within the academic community. The journal publishes original research, reviews, and clinical studies, offering a platform for exploring cutting-edge developments in immunological therapies and experimental methods. Although not currently an open-access journal, it continues to thrive as a valuable resource, reflecting a commitment to disseminating high-quality research and fostering academic discourse in the field. Researchers and professionals alike will find ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS an essential reference source for the latest advancements in immunological research and clinical applications.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, published by Mary Ann Liebert, Inc, stands out as a pivotal resource in the fields of immunology, virology, and cell biology, providing comprehensive insights into cytokine functions and their roles in immune responses. With ISSN 1079-9907 and E-ISSN 1557-7465, the journal aims to disseminate innovative research that advances our understanding of interferon and cytokine biology, a crucial aspect for developing therapeutic strategies against various diseases. Covering a broad scope of research from 1995 to 2024, it boasts a respectable impact factor within its category quartiles, ranking Q2 in Medicine (miscellaneous) and Q3 in the domains of Cell Biology, Immunology, and Virology as of 2023. While it does not provide open access options, the journal remains essential for academics, researchers, and professionals dedicated to exploring the complexities of immune signaling pathways and their implications for health and disease. The journal’s consistent contribution to scientific discourse underscores its importance in elevating query-driven studies to foster advancements in biomedical science.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

IMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.

Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

IMMUNOLOGICAL INVESTIGATIONS, published by Taylor & Francis Inc, is a leading journal in the field of immunology and related medical sciences, with an established presence since 1972. With a focus on cutting-edge research and critical insights in immunological methods and theories, this journal serves as a pivotal platform for researchers, professionals, and students alike. Though it currently holds a Q3 ranking in Immunology and a Q2 ranking in miscellaneous medicine as of 2023, its Scopus rank of #129 out of 236 reflects its dedication to advancing the understanding of immune responses and therapies. The journal's commitment to rigorous peer review and high-quality publications enables it to remain relevant and influential in the ever-evolving landscape of immunological research. Subscription is required to access its extensive archive, which spans critical developments in the field of immunology from 1972 to 2024.

PARASITE IMMUNOLOGY, published by Wiley, is a leading journal in the field of immunology and parasitology, with an ISSN of 0141-9838 and E-ISSN of 1365-3024. Since its inception in 1979, it has played a pivotal role in advancing our understanding of host-parasite interactions, immunological responses to parasitic infections, and the mechanisms of immunological resistance. The journal is adeptly positioned within the academic community, currently holding a prestigious Q2 ranking in Parasitology and a Q3 ranking in Immunology for 2023, indicating its significant influence and relevance. Its comprehensive scope attracts a diverse readership, contributing to the discourse surrounding novel therapeutic approaches and emerging challenges in parasitic diseases. With a consistent convergence of research until 2024, PARASITE IMMUNOLOGY is an essential resource for researchers, professionals, and students seeking to deepen their knowledge and foster collaboration in these dynamic fields. Although it is not an open-access journal, the insights shared within its pages are invaluable for shaping future research trajectories.